Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | CMA1 | P23946 | 2/20 | 0.53 |
| ▸ | REN | P00797 | 1/20 | 0.53 |
| ▸ | TACR1 | P25103 | 3/20 | 0.52 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.51 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.51 |
| ▸ | ITGAL | P20701 | 1/20 | 0.51 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.51 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.51 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.51 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29993706 | 0.92 | DPP3 (0.68) | DPP3SLC6A2REN | |
| SCHEMBL30953538 | 0.91 | DPP3 (0.62) | DPP3SLC6A2REN | |
| SCHEMBL30052255 | 0.90 | DPP3 (0.69) | DPP3TACR1ITGB2ICAM1ITGAL | |
| SCHEMBL10036419 | 0.89 | DPP3 (0.60) | DPP3SLC6A2TACR1CALCRLNTSR2 | |
| SCHEMBL30051571 | 0.88 | DPP3 (0.57) | DPP3MEN1KMT2A | |
| SCHEMBL30288104 | 0.87 | DPP3 (0.71) | DPP3SLC6A2ITGB2ICAM1ITGAL | |
| SCHEMBL29973443 | 0.87 | DPP3 (0.57) | DPP3SLC6A2CALCRLNTSR2NTSR1 | |
| SCHEMBL30050936 | 0.87 | DPP3 (0.69) | DPP3TACR1ITGB2ICAM1ITGAL | |
| SCHEMBL29648960 | 0.86 | DPP3 (0.69) | DPP3NTSR2NTSR1SORT1 | |
| SCHEMBL30610091 | 0.86 | DPP3 (0.69) | DPP3NTSR2NTSR1SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11331371-B2 | Labyrinthopeptins as anti-viral agents | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2022-05-17 | — | — | US | claimed |
| US-11331371-B2 | Labyrinthopeptins as anti-viral agents | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2022-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11331371-B2 | Labyrinthopeptins as anti-viral agents | FUCA1, HAVCR2, FUCA2 | DPP3 767/4885SLC6A2 2256/4885CMA1 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.